Driving Precision Oncology Discoveries
At the Sloan Precision Oncology Institute, we take a broad view of precision oncology. Our definition of precision oncology encompasses a wide range of areas including genetics and genomics, metabolomics, tumor microenvironment, environmental exposures and theranostics. It spans risk, prevention, diagnosis and treatment and is propelled forward by diverse and rich data sets developed in partnership with patients, the communities served by Fred Hutchinson Cancer Center and the wider Cancer Consortium.
“The Sloans' generous gift will help Fred Hutch establish one of the world’s premier precision oncology centers that will bring together our very best basic science, data science, disease-oriented translational science, science of cancer prevention and understanding of the immune system.”
— Dr. Tom Lynch, president and director of Fred Hutch
Key Initiatives
TakePART-NW - Patients and Research Together (Research Consent)
Biorepository/Tissue Donation Program
Molecular Profiling/Genomics Initiative
Clinical Data Templates Project
Research Funding Awards
Early Detection and Precision Interception
Leadership
Peter Nelson, MD
Dr. Nelson is responsible for developing and implementing a world-class precision oncology program at Fred Hutch, in collaboration with consortium partners, UW Medicine and Seattle Children’s. A premier precision oncology program is critical to our ability to understand cancer and develop novel and targeted screening, prevention and treatment strategies for our patients and communities.
Eric Collisson, MD
Dr. Collisson is responsible for growing our preclinical and clinical trials work, focusing on the molecular analysis of cancer. He is engaged in building connections between Fred Hutch, other major cancer centers and cooperative clinical trial consortia to design trials that help drive preclinical ideas into clinical practice.
Inaugural Research Funding Awards
In 2024, the Stuart and Molly Sloan Precision Oncology Institute invited investigators at Fred Hutch Cancer Center, University of Washington and Seattle Children’s Research Institute to submit innovative, forward-thinking proposals centered on Precision Oncology that address a research hypothesis (Ignition Award) or focused on disseminating novel technologies to the research community (Technology Dissemination Award).
Three Ignition and two Technology Dissemination projects were selected for funding.
Events and Announcements
Stuart and Molly Sloan Precision Oncology Institute is hosting a series of symposia to spotlight different areas of Precision Oncology research
The series kicked off on October 1, 2024, with a symposium to explore the current cancer vaccine landscape. The Advances in Cancer Vaccines Symposium featured talks from an international panel of investigators, clinicians, and industry leaders from across the field.
A second symposium highlighting the emerging field of theranostics was held on February 28, 2025. The Theranostics Symposium was organized in partnership with UW Radiology and co-hosted by Drs. Amir Iravani, Director of Theranostics, and Delphine Chen, Director of Molecular Imaging and Therapy, Fred Hutch Cancer Center.
On May 20, 2025 there will be a third symposium focusing on Artificial Intelligence and computational oncology. The AI Symposium is a collobration with our Data Science Lab ("DaSL") and co-hosted by Dr. Jeff Leek, Vice President and Chief Data Officer, Fred Hutch Cancer Center.
Community Advisory Board
Central to the mission of the Sloan Precision Oncology Institute is the integration of the Community Advisory Board that is representative of the communities we serve. The role of the Community Advisory Board is to provide guidance on key initiatives and to ensure that our programs are equitable, inclusive and meet the needs of our patient population.
The Sloan Precision Oncology Institute team recognizes the importance of the patient voice in shaping research directions. Structural barriers and exploitation have resulted in worse health outcomes for minoritized groups. Working together with people from marginalized communities and including their voices as advisors is essential to equity in research practices and improved cancer outcomes for everyone.
Current Community Advisory Board members joined us at our South Lake Union campus for quarterly meetings in 2024. Our first meeting of 2025 was held in March. Members discussed our key initiatives and provided valuable feedback on patient materials and education. Our board meets three to four times annually.
We are extending our invitation to join our Community Advisory Board. Eligible members are current patients with cancer, cancer survivors, family members or caregivers of a person with cancer.
Contact Us
For more information about our precision oncology efforts, please contact us.